Opinion|Videos|September 24, 2025

Future Treatment of Patients With Alopecia Areata

Panelists discuss how the introduction of Janus kinase (JAK) inhibitor therapies will likely change treatment algorithms for alopecia areata (AA), with insights on how payers should plan for coverage in the coming years and explore the biggest unmet needs for patients with AA and potential improvements in care.

Video content above is prompted by the following:

  1. McMichael: How do you see treatment algorithms changing with the introduction of JAK inhibitor therapies?
    1. How do you think payers should anticipate covering AA in the next few years?
  2. Friedland: What do you see as the biggest unmet needs for patients with AA and how can these be improved in the future?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo